ASH 2015 | Phase II trial: ATIR for ALL following haploidentical hematopoietic cell transplant
Denis-Claude Roy
• 4 Dec 2015
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Roy Denis-Claude, MD, from Maisonneuve-Rosemont Hospital and Montreal University, Montreal, QC, Canada, discusses the results of an open-label, multi-center phase 2 clinical trial, which showed donor lymphocytes depleted of alloreactive T cells (ATIR101) reduced transplant-related mortality and improved overall survival in haploidentical hematopoietic stem cell transplantation (HSCT) for patients with high-risk acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL), using an immunosuppressant-free transplant regimen.
